How useful are unconventional cancer treatments?

European Journal of Cancer

Volumn 35, Issue 11, 1999, Pages 1608-1613

  Ernst, E ^a   Cassileth, B R ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Alternative medicine; Cancer; Complementary medicine; Diet; Palliative therapy; Unconventional drugs

Indexed keywords

HYDRAZINE SULFATE; LAETRILE; PLANT EXTRACT; RETINOL DERIVATIVE; SOMATOSTATIN; THYMOPENTIN; THYMUS EXTRACT;

ADOPTIVE IMMUNOTHERAPY; ALTERNATIVE MEDICINE; ARTICLE; CANCER; CANCER PALLIATIVE THERAPY; CANCER THERAPY; DIET; DRUG EFFICACY; DRUG SAFETY; GARLIC; GINSENG; HUMAN; OXYGENATION; PRIORITY JOURNAL; SHARK; TEA; VEGETARIAN DIET; VISCUM ALBUM;

COMPLEMENTARY THERAPIES; HUMANS; NEOADJUVANT THERAPY; NEOPLASMS; PALLIATIVE CARE;

EID: 0032832964     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00198-7     Document Type: Article

References (81)

1. Ernst E., Resch K.L., Mills S.et al. Complementary medicine - a definition. Br. J. Gen. Pract. 45:1995;506.
2. Astin J.A. Why patients use alternative medicine. Results of a national study. J. Am. Med. Assoc. 279:1998;1548-1553.
3. MacLennan A.H., Wilson D.H., Taylor A.W. Prevalence and cost of alternative medicine in Australia. Lancet. 347:1996;569-573.
4. Häusermann D. Wachsendes Vertrauen in Naturheilmittel. Dtsch Ärzteblatt. 94:1997;1857-1858.
5. Ernst E. Complementary AIDS therapies. the good, the bad and the ugly Int. J. STD & AIDS. 8:1997;281-285.
6. Cassileth B. The social implications of questionable cancer therapies. Cancer. 63:1989;1247-1250.
7. Ernst E., Willoughby M., Weihmayr T.H. Nine possible reasons for choosing complementary medicine. Perfusion. 8:1995;356-358.
8. Gray R.E., Fitch M., Greenberg M. Physician perspectives on unconventional cancer therapies. J. Palliative Care. 13:1997;14-21.
9. Gentile A. Unconventional cancer therapies. Chronic Dis. Canada. 18:1997;93-94.
10. Burkhard B. Nicht-konventionelle Verfahren in der Onkologie. Onkologie. 1:1995;583-589.
11. Ernst E. Complementary cancer treatments, hope or hazard? Clin. Oncol. 7:1995;259-263.
12. Schimpff SC. Complementary medicine. Current opinion in oncology. 1997, 9, 327-331.
13. Ernst E., Cassileth B.R. The prevalence of complementary/alternative medicine in cancer. Cancer. 83:1998;777-782.
14. Risberg T., Lund E., Wist E., Kaasa S., Wilsgaard T. Cancer patients use of nonproven therapy. A 5-year follow-up study. J. Clin. Oncol. 16:1998;6-12.
15. Bagenal F.S., Easton D.F., Harris E., Chilvers C.E.D., McElwain T.J. Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet. 336:1990;606-610.
16. Cassileth B.R., Lusk E.J., Guerry D.et al. Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N. Engl. J. Med. 324:1991;1180-1185.
17. Li J.H. A study on treatment of lung cancer by combined therapy of traditional Chinese medicine and chemotherapy. Chung-Kuo Hsi I Chieh Ho Tsa Chih. 16:1996;136-138.
18. Moertel C.G., Fleming T.R., Rubin J. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N. Engl. J. Med. 306:1982;201-206.
19. Cassileth B.R. Alternative and complementary cancer treatments. The Oncologist. 1:1996;173-179.
20. Lee A., Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science. 221:1983;1185-1187.
21. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3:1992;65-71.
22. Gardner M.L.G. Gastrointestinal adsorption of intact proteins. Ann. Rev. Nutr. 8:1988;329-350.
23. Holt S. Shark cartilage and neutriceutical update. Alt. Compl. Ther. 1:1995;414-416.
24. Cassileth BR. The Alternative Medicine Handbook. New York, WW Norton, 1998.
25. Mathews J. Media feeds frenzy over shark cartilage as cancer treatment. J. Natl. Cancer Inst. 85:1993;1190-1191.
26. Boik J. Cancer and Natural Medicine. A Textbook for Basic Science and Clinical Research. Oregon Medical Press, 1995.
27. Ashar B., Vargo E. Shark cartilage - induced hepatitis. Ann. Int. Med. 125:1996;780-781.
28. Stirpe F., Sandvig K., Olses S., Pihl A. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J. Biol. Chem. 257:1982;13271-13277.
29. Mannel D.N., Becker H., Gundt A., Kist A., Franz H. Induction of tumor necrosis factor expression by a lectin from Viscum album. Cancer Immunother. 33:1991;177-182.
30. Beuth J., Ko H.L., Gabius H.J., Pulverer G. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems. In Vivo. 5:1991;29-32.
31. Kuttan G., Vasudevan D.M., Kuttan R. Isolation and identification of a tumour reducing component from mistletoe extract (Iscador). Cancer Lett. 41:1988;307-314.
32. Kaegi E. Unconventional therapies for cancer: Iscador. Can med Ass J. 158:1998;1157-1159.
33. Kleijnen J., Knipschild P. Mistletoe treatment for cancer. review of controlled trials in humans Phytomedicine. 1:1994;255-260.
34. Tas M.P., Simons P.J., Balm F.J., Dexhage H.A. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer. Cancer Immunol. 36:1993;108-114.
35. Gieldanowski J., Lemmel E.M., Blaszczyk B. The influence of thymus hormones on the NK cells activity. Arch. Immunol. Ther. Exp. Warsz. 35:1987;57-61.
36. Molto L.M., Carballido J.A., Mazano L., Olivier C., Lapuerta M., Alvarez-Mon M. Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder. Int. J. Immunopharmacol. 15:1993;335-341.
37. Favalli C., Jezzi T., Mastino A., Rinaldi-Garaci C., Riccardi C. Modulation of natural killer activity by thymosin Alpha 1 and Interferon. Cancer Immunol. Immunother. 20:1985;189-192.
38. Gomes R.M., Shinzato T.O., Grynberg N.F. Growth control of experimental tumour by syngeneic thymocyte extracts. Braz. J. Med. Biol. Res. 20:1987;449-451.
39. Klein A.S., Lang R., Eshel I., Sharabi Y., Shoham J. Modulation of immune response and tumour development in tumour bearing mice treated by the thymic factor thymostimulin. Cancer Res. 47:1987;3351-3356.
40. Federico M., Gobbi P.G. Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Am. J. Clin. Oncol. 18:1995;8-14.
41. Ernst E. Thymus therapy for cancer? A criteria-based, systematic review. Eur. J. Cancer. 33:1997;531-534.
42. Kaegi E. Unconventional therapies for cancer: 1 Essiac. Can med Ass J. 158:1998;897-902.
43. Gold J. Proposal treatment of cancer by inhibition of gluconeogenesis. Oncology. 22:1968;185-207.
44. Kaegi E. Unconventional therapies for cancer: 4 Hydrazine sulfate. Can med Ass J. 158:1998;1327-1329.
45. Kosty M.P., Fleishman S.B., Herndon II J.E., Coughlin K. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer. a randomised placebo-controlled, double-blind phase III study of the cancer and Leukemia Group B J. Clin. Oncol. 12:1994;1113-1120.
46. Loprinzi C.L., Kuross S.A., O'Fallon J.R., Gesme D. Randomised placebo-controlled evaluation of hydrazine sulfate on patients with advanced colorectal cancer. J. Clin. Oncol. 12:1994;1121-1125.
47. Loprinzi C.L., Goldberg R.M., Su J.Q., Mailliard J.A. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J. Clin. Oncol. 12:1994;1126-1129.
48. Kaegi E. Unconventional therapies for cancer: 6 714-X. Can med Ass J. 158:1998;1621-1624.
49. Ernst E., Cassileth B. Cancer diets, fads and facts. Cancer Prevent. Int. 2:1996;181-187.
50. Hildenbrand G. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson. a retrospective review Altern. Ther. Health Med. 4:1995;29-37.
51. Downer S.M., Cody M.M., McCluskey P. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. Br. Med. J. 309:1994;86-89.
52. Cassileth B.R., Chapman C.C. Alternative and complementary cancer therapies. Cancer. 77:1996;1026-1034.
53. Russell R. Notes on the Causation of Cancer. London, Longmans, Green, 1916.
54. Thorogood M., Mann J., Appleby P., McPherson K. Risk of death from cancer and ischaemic heart disease in meat and non meat-eaters. Br. Med. J. 108:1994;1667-1671.
55. Modan B. Diet and cancer. causal relation or just wishful thinking? Lancet. 340:1992;162-163.
56. Ernst E. Risks and benefits of vegetarianism. Br. J. Hosp. Med. 58:1997;372-374.
57. Schaffer E.M., Liu J.Z., Green J., Dangler ChA., Milner J.A. Garlic and associated allylsulfur components inhibit N-methyl-N-nitrosourea induced mammary carcinogenesis. Cancer Lett. 102:1996;199-204.
58. Wattenberg LW, Hanley AB, Barany G. Inhibition of carcinogenesis by some minor dietary constituents. In Hayashi Y, Nagao M, Sugimura T, eds. Diet, Nutrition and Cancer. Tokyo, Jap. Sci. Goc. Press, 1986, 193-203.
59. Maurya A.K., Singh S.V. Differential induction of glutathione transferase isoenzymes of mice stomach by diallyl sulfide, a naturally occurring anticarcinogen. Cancer Lett. 57:1991;121-129.
60. Amagase H., Schaeffer E.M., Milner J.A. Dietary components modify the ability of garlic to suppress 7,12-dimethylbenz(a)anthracene-induced mammary DNA adducts. J. Nutr. 126:1996;817-824.
61. Cavallito C.J., Bailey J.H. Allicin, the antibacterial principle of allium sativum. J. Am. Chem. Soc. 66:1944;1950-1951.
62. Steinmetz K.A., Kushi L.H., Bostick R.M., Folsom A.R., Potter J.D. Vegetables, fruit, and colon cancer in the Iowa Women's Health Study. Am. J. Epidemiol. 139:1994;1-15.
63. Cellini L., Di Campli E., Masulli M., Bartolomeo S., Allocati N. Inhibition of Heliobacter pylori by garlic extract. FEMS Immunol. Med. Microbiol. 13:1996;273-277.
64. Ernst E. Can allium vegetables prevent cancer? Phytomedicine. 4:1997;79-83.
65. Wang Z.Y., Huang M.T., Ho C.T.et al. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Lett. 28:1995;27-31.
66. Jain A.K., Shimoi K., Nakamura Y.et al. Crude tea extracts decrease the mutagenic activity of N-methyl-N-nitro-N-nitrosoguanidine in vitro and in intragastric tract of rats. Mutat. Res. 210:1989;1-8.
67. Sazuka M., Murakami S., Isemura M., Satoh K., Nukiwa T. Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. Cancer Lett. 98:1995;27-31.
68. Gao Y.T., McLaughlin J.K., Blot W.J. Reduced risk of esophageal cancer associated with green tea consumption. J. Natl. Cancer Inst. 86:1994;855-858.
69. Weisburger J.H. Introduction: physiological and pharmacological effects of Camellia sinensis (tea). first international symposium Prevent. Med. 21:1992;329-330.
70. Yang C.S., Wang Z.Y. Tea and cancer. J. Natl. Cancer Inst. 85:1993;1038-1049.
71. Kaegi E. Unconventional therapies for cancer: 2 Green tea. CMAJ. 158:1998;1621-1624.
72. Yun T.K. Experimental and epidemiological evidence of the cancer-preventive effects of Panax ginseng C. A. Meyer. Nutr. Rev. 54:1996;71-81.
73. Lee Y.S., Chung I.S., Lee I.R. Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng. Anticancer Res. 17:1997;323-331.
74. Yun T-K., Choi S-Y. Non-organ specific cancer prevention of ginseng. a prospective study in Korea Int. J. Epidemiol. 27:1998;359-364.
75. Stoll B.A. Can unorthodox cancer therapy improve quality of life? Ann. Oncol. 4:1993;121-123.
76. Hürny Ch., Heusser P., Bernhard J., Castiglione M., Cerny Th. Verbessern nicht-konventionelle Zusatztherapien die Lebensqualität von Krebspatienten? Schweiz. Med. Wochenschr. 124(Suppl 62):1994;55-63.
77. Connell C. Art therapy as part of a palliative care programme. Palliat. Med. 6:1992;18-25.
78. Clover A., Last P., Fisher P., Wright S., Boyle H. Complementary cancer therapy. a pilot study of patients, therapies and quality of life Complement Ther. Med. 3:1995;129-133.
79. Genuis M.L. The use of hypnosis in helping cancer patients control anxiety, pain, and emesis. a review of recent empirical studies Am. J. Clin. Hypn. 37:1995;317-325.
80. Sloman R. Relaxation and the pain of cancer relief. Relieving Cancer Pain. 30:1995;697-709.
81. Syrjala K.L., Donaldson G.W., Davis M.W., Kippes M.E., Carr J.E. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment. a controlled clinical trial Pain. 63:1995;189-198.